12.01
+0.75(+6.66%)
Currency In USD
Address
805 Las Cimas Parkway
Austin, TX 78746
United States of America
Phone
512 942 2935
Website
Sector
Healthcare
Industry
Biotechnology
Employees
69
First IPO Date
April 07, 2016
| Name | Title | Pay | Year Born |
| Mr. Jeffrey M. Goldberg | Pres, Chief Executive Officer & Director | 617,729 | 1973 |
| Mr. Michael C. Hanley M.B.A. | Chief Commercial Officer & Chief Bus. Officer | 577,417 | 1973 |
| Dr. Leslie S. Sloan Ph.D. | Chief Operating Officer | 626,940 | 1971 |
| Dr. Linda Neuman M.D., MBA | Chief Medical Officer | 0 | N/A |
| Dr. Josie Gayton Ph.D. | Senior Vice President of Program Strategy, Operations & Chief of Staff | 0 | N/A |
| Dr. Scott W. Rowlinson | Vice President of Research | 0 | 1968 |
| Dr. F. Andrew Dorr | Executive Officer | 0 | 1953 |
| Ms. Tricia Sterling | Vice President of Patient Affairs | 0 | N/A |
| Dr. Cameron Turtle DPHIL, Ph.D. | Chief Operating Officer & Principal Executive Officer | 0 | 1990 |
| Dr. Kelly Boothe Ph.D. | Senior Director of Corporate Communications & Investor Relations | 0 | N/A |
| Mr. Scott L. Burrows | Chief Financial Officer | 0 | 1977 |
| Joey Perrone | Vice President of Finance & Investor Relations | 0 | N/A |
| Ms. Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary | 0 | 1983 |
| Ms. Cortney Caudill M.B.A. | Chief Product Officer | 0 | N/A |
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.